Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS

Table 1 Case demographics of cases used in the study

Cases	Disease group	Age at onset	Age at death	Disease duration	Gender	Post-mortem delay (hours)
1	FTLD-FUS	41	43	2	F	55
2	FTLD-FUS	44	46	2	M	96
3	FTLD-FUS	63	59	6	F	2
4	FTLD-FUS	43	46	3	F	30
5	FTLD-FUS	69	72	3	F	90
6	FTLD-FUS	66	69	3	F	102
7	FTLD-FUS	49	55	6	F	3.5
8	FTLD-FUS	43	53	10	F	96
9	FTLD-FUS	55	58	3	F	N/A
10	FTLD-FUS	40	51	11	M	12
11	FTLD-FUS	44	51	7	M	24
12	FTLD-FUS	47	53	6	M	5
13	FTLD-FUS	51	60	9	M	48
FTLD-FUS summary		50 (9.5)	55 (8.5)	5.5 (3)	5 M:8F	47 (40)
14	FTLD-TDP A	66	74	8	F	86
15	FTLD-TDP A	43	45	2	M	26
16	FTLD-TDP A	53	63	10	M	77
17	FTLD-TDP A	62	68	6	M	99
18	FTLD-TDP A	58	67	9	F	115
19	FTLD-TDP A	56	67	11	F	85.5
20	FTLD-TDP A	57	62	5	F	63
21	FTLD-TDP A	66	71	5	M	52
22	FTLD-TDP A	58	66	8	F	107
23	FTLD-TDP A	47	53	6	M	34
24	FTLD-TDP A	53	61	8	M	72.5
25	FTLD-TDP A	57	62	5	M	93
26	FTLD-TDP A	62	72	10	M	97.5
27	FTLD-TDP A	49	55	6	M	29
28	FTLD-TDP A	75	78	3	F	36
29	FTLD-TDP A	83	87	4	F	69
30	FTLD-TDP A	57	63	6	F	85
31	FTLD-TDP A	72	79	7	F	50
32	FTLD-TDP A	62	68	6	F	100
FTLD-TDP A summary		59 (10)	66 (10)	6.6 (2.4)	9 M:10F	71 (28)
33	FTLD-TDP B	67	69	2	M	70
34	FTLD-TDP B	63	67	4	F	45.5
35	FTLD-TDP B	63	83	20	F	45
FTLD-TDP B summary		64.3 (2.3)	73 (8.7)	8.6 (9.8)	1 M:2F	53.5 (14)
36	FTLD-TDP C	58	73	15	F	38
37	FTLD-TDP C	59	73	14	F	84
38	FTLD-TDP C	64	78	14	M	27
39	FTLD-TDP C	64	74	10	M	19
40	FTLD-TDP C	50	65	15	M	52
41	FTLD-TDP C	61	66	5	M	71
42	FTLD-TDP C	44	67	23	M	76
FTLD-TDP C summary		57.1 (7.5)	70.8 (4.9)	13.7 (5.5)	5 M:2F	52 (25)
43	Control	80	N/A	N/A	M	16
44	Control	79	N/A	N/A	F	89
45	Control	80	N/A	N/A	F	49
46	Control	93	N/A	N/A	F	30
47	Control	73	N/A	N/A	F	24
48	Control	83	N/A	N/A	F	20
Control summary		81.3 (6.6)	N/A	N/A	1 M:5F	14 (3.5)

ISSN: 2051-5960